Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases

Fuminori Abe, Gregory Alvord, Michinori Koyama, Akira Matsuda, James E. Talmadge

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Bestatin is a low molecular weight aminopeptidase inhibitor originally isolated from culture filtrates of Streptomyces olivoreticuli. The serum pharmacokinetics in mice are dependent on route of administration, with a short t1/2 (1.69 min t1/2α and 12.8 min t1/2β), but a high initial serum level following i.v. administration. When administered via the i.p., s.c., i.m., or p.o. routes of administration, bestatin had serum t1/2βs of 8.56, 16.91, 19.25, or 15.4 min, respectively. The maximum area under the curve (concentration×time) occurred following i.v. and i.m. administration, with a lower level following p.o. or i.p. administration. Bestatin had therapeutic activity for experimental metastases, not only following i.v., i.p., and i.m. routes of administration but also following oral administration. Because of its brief serum t1/2, bestatin's therapeutic activity depends on aggressive (either daily or twice daily injection, especially following p.o. administration) and high-dose administration. Thus, the rate-limiting aspect of bestatin's therapeutic activity appears to be associated with its pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)29-33
Number of pages5
JournalCancer Immunology Immunotherapy
Volume28
Issue number1
DOIs
StatePublished - Jan 1 1989

Fingerprint

Pharmacokinetics
Neoplasm Metastasis
Serum
Therapeutics
Aminopeptidases
Streptomyces
Area Under Curve
Oral Administration
Molecular Weight
ubenimex
Injections

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases. / Abe, Fuminori; Alvord, Gregory; Koyama, Michinori; Matsuda, Akira; Talmadge, James E.

In: Cancer Immunology Immunotherapy, Vol. 28, No. 1, 01.01.1989, p. 29-33.

Research output: Contribution to journalArticle

Abe, Fuminori ; Alvord, Gregory ; Koyama, Michinori ; Matsuda, Akira ; Talmadge, James E. / Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases. In: Cancer Immunology Immunotherapy. 1989 ; Vol. 28, No. 1. pp. 29-33.
@article{9c6b72d9a75943d4917ef544bb92d094,
title = "Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases",
abstract = "Bestatin is a low molecular weight aminopeptidase inhibitor originally isolated from culture filtrates of Streptomyces olivoreticuli. The serum pharmacokinetics in mice are dependent on route of administration, with a short t1/2 (1.69 min t1/2α and 12.8 min t1/2β), but a high initial serum level following i.v. administration. When administered via the i.p., s.c., i.m., or p.o. routes of administration, bestatin had serum t1/2βs of 8.56, 16.91, 19.25, or 15.4 min, respectively. The maximum area under the curve (concentration×time) occurred following i.v. and i.m. administration, with a lower level following p.o. or i.p. administration. Bestatin had therapeutic activity for experimental metastases, not only following i.v., i.p., and i.m. routes of administration but also following oral administration. Because of its brief serum t1/2, bestatin's therapeutic activity depends on aggressive (either daily or twice daily injection, especially following p.o. administration) and high-dose administration. Thus, the rate-limiting aspect of bestatin's therapeutic activity appears to be associated with its pharmacokinetics.",
author = "Fuminori Abe and Gregory Alvord and Michinori Koyama and Akira Matsuda and Talmadge, {James E.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1007/BF00205797",
language = "English (US)",
volume = "28",
pages = "29--33",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases

AU - Abe, Fuminori

AU - Alvord, Gregory

AU - Koyama, Michinori

AU - Matsuda, Akira

AU - Talmadge, James E.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Bestatin is a low molecular weight aminopeptidase inhibitor originally isolated from culture filtrates of Streptomyces olivoreticuli. The serum pharmacokinetics in mice are dependent on route of administration, with a short t1/2 (1.69 min t1/2α and 12.8 min t1/2β), but a high initial serum level following i.v. administration. When administered via the i.p., s.c., i.m., or p.o. routes of administration, bestatin had serum t1/2βs of 8.56, 16.91, 19.25, or 15.4 min, respectively. The maximum area under the curve (concentration×time) occurred following i.v. and i.m. administration, with a lower level following p.o. or i.p. administration. Bestatin had therapeutic activity for experimental metastases, not only following i.v., i.p., and i.m. routes of administration but also following oral administration. Because of its brief serum t1/2, bestatin's therapeutic activity depends on aggressive (either daily or twice daily injection, especially following p.o. administration) and high-dose administration. Thus, the rate-limiting aspect of bestatin's therapeutic activity appears to be associated with its pharmacokinetics.

AB - Bestatin is a low molecular weight aminopeptidase inhibitor originally isolated from culture filtrates of Streptomyces olivoreticuli. The serum pharmacokinetics in mice are dependent on route of administration, with a short t1/2 (1.69 min t1/2α and 12.8 min t1/2β), but a high initial serum level following i.v. administration. When administered via the i.p., s.c., i.m., or p.o. routes of administration, bestatin had serum t1/2βs of 8.56, 16.91, 19.25, or 15.4 min, respectively. The maximum area under the curve (concentration×time) occurred following i.v. and i.m. administration, with a lower level following p.o. or i.p. administration. Bestatin had therapeutic activity for experimental metastases, not only following i.v., i.p., and i.m. routes of administration but also following oral administration. Because of its brief serum t1/2, bestatin's therapeutic activity depends on aggressive (either daily or twice daily injection, especially following p.o. administration) and high-dose administration. Thus, the rate-limiting aspect of bestatin's therapeutic activity appears to be associated with its pharmacokinetics.

UR - http://www.scopus.com/inward/record.url?scp=0024465227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024465227&partnerID=8YFLogxK

U2 - 10.1007/BF00205797

DO - 10.1007/BF00205797

M3 - Article

C2 - 2909281

AN - SCOPUS:0024465227

VL - 28

SP - 29

EP - 33

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -